Cited 7 times in
Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이관식 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2015-04-24T17:13:43Z | - |
dc.date.available | 2015-04-24T17:13:43Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104997 | - |
dc.description.abstract | BACKGROUND/AIMS: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon alpha-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. METHODS: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon alpha-2a (180 microgram/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon alpha-2a (180 microgram/week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). RESULTS: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%; non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was 32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using > or =80% of the peginterferon dose was significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not change based on genotype. CONCLUSIONS: We suggest that using at least 80% of the peginterferon alpha-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 203~211 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiviral Agents/administration & dosage* | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis C, Chronic/virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Interferon-alpha/administration & dosage* | - |
dc.subject.MESH | Interferon-alpha/adverse effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Polyethylene Glycols/administration & dosage* | - |
dc.subject.MESH | Polyethylene Glycols/adverse effects | - |
dc.subject.MESH | RNA, Viral/blood | - |
dc.subject.MESH | Recombinant Proteins | - |
dc.subject.MESH | Ribavirin/administration & dosage* | - |
dc.subject.MESH | Ribavirin/adverse effects | - |
dc.title | Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jung Hyun Kwon | - |
dc.contributor.googleauthor | Si Hyun Bae | - |
dc.contributor.googleauthor | Jong Young Choi | - |
dc.contributor.googleauthor | Seung Kew Yoon | - |
dc.contributor.googleauthor | Kwan Soo Byun | - |
dc.contributor.googleauthor | Seung Woon Paik | - |
dc.contributor.googleauthor | Young Suk Lim | - |
dc.contributor.googleauthor | Han Chu Lee | - |
dc.contributor.googleauthor | Kwang Hyub Han | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.identifier.doi | 10.3904/kjim.2009.24.3.203 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J02883 | - |
dc.identifier.eissn | 2005-6648 | - |
dc.identifier.pmid | 19721856 | - |
dc.subject.keyword | Hepatitis C | - |
dc.subject.keyword | Koreans | - |
dc.subject.keyword | Peginterferon alfa-2a | - |
dc.subject.keyword | Ribavirin | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 203 | - |
dc.citation.endPage | 211 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.24(3) : 203-211, 2009 | - |
dc.identifier.rimsid | 55137 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.